Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NRCT-201XR
- Development stage
- Unknown
- Lead developer
- Neurocentria
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NRCT-201XR is an extended-release small molecule drug candidate being developed by Neurocentria for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The drug utilizes a novel mechanism of action by elevating intracellular magnesium (Mg2+) levels specifically within synaptic terminals. This elevation is intended to increase synaptic density and plasticity, addressing the neurobiological deficits associated with ADHD. As of late 2022, NRCT-201XR was in Phase 2 clinical development following the submission of an Investigational New Drug (IND) application. It is part of a broader pipeline of magnesium-based therapeutic candidates that includes NRCT-101SR and NRCT-202XR.
Beyond the preview
Go deeper on NRCT-201XR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NRCT-201XR.